Maastricht – March 19, 2015 – PharmaCell B.V., announced today that it finalized an agreement with ImmunoCellular Therapeutics Ltd. to support its pivotal phase III clinical trial in Europe with ICT-107. ICT 107 is a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the commonest and deadliest forms of brain cancer. Under the terms of the agreement, PharmaCell will perform a Technology Transfer from its US-based contract manufacturing partner to its newly acquired Geleen facility (The Netherlands), and support the subsequent clinical trial with ICT-107.

For more information:
Alexander Vos
Chief Executive Officer

Soenke Brunswieck, PhD
Director Business Development
+31 43 35 09910

PharmaCell_Press_Release_IMUC March 2015 V2